Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Blair William & Co. IL

Blair William & Co. IL lessened its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 22.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 67,946 shares of the company’s stock after selling 19,355 shares during the quarter. Blair William & Co. IL owned 0.11% of Twist Bioscience worth $3,157,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of TWST. Van ECK Associates Corp grew its position in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after buying an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience during the 3rd quarter valued at $34,000. US Bancorp DE grew its holdings in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after acquiring an additional 601 shares in the last quarter. Beaird Harris Wealth Management LLC bought a new stake in shares of Twist Bioscience in the 3rd quarter worth about $95,000. Finally, KBC Group NV raised its stake in shares of Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after purchasing an additional 1,226 shares in the last quarter.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 1,726 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $71,939.68. Following the completion of the sale, the chief executive officer now directly owns 660,966 shares of the company’s stock, valued at approximately $27,549,062.88. This represents a 0.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Robert Chess sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the transaction, the director now owns 16,641 shares in the company, valued at $832,050. This represents a 23.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,799 shares of company stock worth $1,593,944. 3.01% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TWST. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Robert W. Baird raised their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $54.40.

Twist Bioscience Stock Down 2.7 %

TWST stock opened at $39.26 on Tuesday. The stock has a market cap of $2.34 billion, a PE ratio of -11.62 and a beta of 2.15. The firm’s 50-day simple moving average is $44.99 and its 200 day simple moving average is $45.33. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience’s revenue was up 24.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.75) earnings per share. As a group, sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.